Lexicon Pharmaceuticals Inc

Research Lexicon Pharmaceuticals Inc (LXRX) on Bullrun: market cap USD 1.04B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 1.04B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 49.80M-USD 50.34M-USD 67.85M99.4%-0.14USD 34.33MUSD 54.00MUSD 107.54M
FY2024USD 6.00M-USD 200.40M-USD 179.81M89.7%-0.63USD 66.66MUSD 100.30MUSD 145.95M
FY2023USD 1.11M-USD 177.12M-USD 162.37M92.3%-0.8USD 22.47MUSD 99.51MUSD 93.11M
FY2022USD 0-USD 101.94M-USD 90.18Mn/a-0.62USD 46.35MUSD 48.58MUSD 117.12M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 1.04Bn/an/an/a
20252025-12-31USD 417.99Mn/an/an/a
20242024-12-31USD 267.50Mn/an/an/a
20232023-12-29USD 373.36Mn/an/an/a
20222022-12-30USD 360.47Mn/an/an/a
20212021-12-31USD 586.73Mn/an/an/a

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Lexicon Pharmaceuticals Inc's market cap?

Lexicon Pharmaceuticals Inc's market capitalization is USD 1.04B.

What does Lexicon Pharmaceuticals Inc do?

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.